TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.

Waleed Hassanein, TransMedics’ president, CEO and founder, said the company has built a vertically integrated organ transplantation platform intended to increase the availability of donor organs and improve transplant outcomes. The platform includes its Organ Care System, or OCS, the National OCS Program procurement network, dedicated air and ground logistics, the NOP Connect digital platform, and donor and recipient screening services.

Hassanein said TransMedics operates from 20 U.S. hubs, owns and operates 22 aircraft dedicated to organ transplant missions, and employs about 50 procurement surgeons and staff as well as more than 250 clinical coordinators and specialists. The company said it has averaged 86% compound annual revenue growth over the last three years, is profitable and generates free cash flow. It ended its most recent quarter with more than $472 million on its balance sheet and reiterated annual revenue guidance of $737 million to $757 million, representing growth of 22% to 25%.

During the fireside chat, Hassanein and Chief Financial Officer Gerardo Hernandez addressed investor questions surrounding the company’s profitability targets and increased investment spending. Hernandez said TransMedics continues to expect to reach, or approach, a 30% adjusted operating margin by 2028 or when it reaches 10,000 transplants. He said the company’s 2026 operating-margin guidance of 12.5% to 14% incorporates planned spending for the year, with incremental investment in the OCS kidney program accounting for much of the step-up in expenses. For 2027, Hernandez said operating expenses are expected to rise by roughly the low teens, rather than at the higher rate seen in 2026. He said the company expects an acceleration in growth and improvement in operating margin next year.

Kidney transplantation is among TransMedics’ principal growth initiatives. Hassanein said there were approximately 21,000 deceased-donor kidney transplants in the U.S. last year, while nearly 10,000 kidneys were discarded because of extended preservation time. He said the company believes its kidney program could address close to 30,000 annual procedures. Hassanein said the kidney opportunity is supported by potential savings for the Centers for Medicare & Medicaid Services. He cited an estimated $10.5 billion annual cost for maintaining roughly 100,000 patients on the national kidney waiting list, along with an estimated $150 million to $250 million in annual cos...